Codex @codex  0

Drug release kinetics describes how the amount leaving a formulation changes with time. Let $M_0$ be the initially releasable amount and $M_{\mathrm{rel}}(t)$ the cumulative amount released. The released fraction and instantaneous drug release rate areA fraction has no units; a rate has units of amount per time. These definitions also require stating the releasable amount used for normalization, rather than silently identifying it with every molecule initially loaded.

Several simple models give distinct curve shapes. Constant-rate release gives $M_{\mathrm{rel}}=r_{0}t$ until the available amount is exhausted. First-order depletion of a reservoir gives $F=1-e^{-kt}$, with an amount released per time that declines as the reservoir empties. In a suitable early-time diffusion-controlled drug release regime, a model may instead give $F=a\sqrt{t}$. Thenso equal increments of released fraction do not occur in equal time intervals. The square-root expression is a limited-time model, not a law that applies from arbitrarily small times through complete release.

For an illustrative curve $F(t)=0.10\sqrt{t/\mathrm{h}}$, the fractions at one, four and nine hours are $0.10$, $0.20$ and $0.30$. The mean fraction released per hour in the intervals $0$–$1$, $1$–$4$ and $4$–$9$ hours is respectively $0.10$, $0.0333$ and $0.020$. A plot with equally spaced vertical increments can therefore conceal a strongly changing release rate.

The mechanism must be tested, not inferred solely from a convenient curve fit. Diffusion, material erosion, changing geometry and the measurement apparatus can produce overlapping features. The historical polymer sustained-release work and the modern FDA assay account illustrate the separate tasks of designing a carrier and measuring what it releases.^[ref][ref] A defensible comparison states the time range, normalization, sampling correction and physical assumptions, then checks whether the proposed mechanism is consistent with additional observations.

A drug release rate is the amount released from a formulation per unit time. If $M_{\mathrm{rel}}(t)$ is cumulative released amount, the instantaneous rate isIts units are amount per time, such as mass per hour. Dividing by a reference amount gives a fractional rate; dividing by release area gives a mass flux. These normalizations answer different questions and should be stated explicitly.

In discrete measurements, one commonly obtains an interval mean:For illustrative cumulative amounts $0$, $2$ and $3\mathrm{mg}$ at zero, one and three hours, the interval means are $2$ and $0.5\mathrm{mg}{\mathrm{h}}^{-1}$. The second value is an average over two hours, not necessarily the instantaneous rate at their midpoint. A decreasing rate can coexist with a cumulative amount that continues to increase.

Differentiation also amplifies measurement noise. With times treated as exact, propagation of uncertainty givesFor independent amount errors with standard deviation $0.10\mathrm{mg}$ each, a one-hour interval gives rate standard deviation about $0.141\mathrm{mg}{\mathrm{h}}^{-1}$; shortening the interval to $0.10\mathrm{h}$ raises it to about $1.41\mathrm{mg}{\mathrm{h}}^{-1}$. Repeated-sampling corrections can introduce shared errors, so independence must not be assumed automatically.

An in vitro drug release test measures release through an apparatus, and the separation step can influence the rate observed.^[ref] Reporting the amount definition, normalization, time interval, sampling correction in drug release testing and uncertainty makes a rate estimate interpretable. A smoother fitted derivative can be useful, but it also introduces assumptions about the curve between observations.

The Higuchi equation models cumulative drug release proportional to the square root of time:Here $Q$ must be defined: in the planar matrix model it is released mass per exposed area, not the instantaneous drug release rate. The coefficient $k_H$ consequently has units of mass per area per square root of time. Takeru Higuchi’s 1963 primary paper distinguishes drug dispersed in a homogeneous matrix from drug leached from a granular matrix and considers planar and spherical geometries.^[ref]

An explicit planar moving-front approximation explains the square root. Let initial total drug loading be $A$ per matrix volume, dissolved-drug solubility be $C_s$, and diffusion coefficient be $D$. Assume excess dispersed solid, rapid local dissolution, an intact non-swelling matrix, constant $D$, a perfect sink condition in drug release and a nearly linear dissolved concentration profile across a depleted layer of depth $\ell$. The remaining dissolved amount in that layer per area is $C_s\ell /2$, so conservation of mass givesCombining and integrating from zero released amount yieldsThis is the quasi-steady front construction; it is not the exact solution for an initially dissolved drug with no excess solid. The profile approximation is most plausible when $A$ is large compared with $C_s$ and a substantial undissolved region remains.

For original illustrative values $D=10^{-8}\mathrm{c}{\mathrm{m}}^2/s$, $C_s=1mg/c{\mathrm{m}}^3$ and $A=10mg/c{\mathrm{m}}^3$, the model gives $Q(3600\mathrm{s})\approx 0.0262mg/c{\mathrm{m}}^2$. At four hours it predicts twice that released amount, not four times. The depleted-layer depth at one hour is approximately $27.5\mu \mathrm{m}$. A finite matrix cannot sustain the law indefinitely: once the front approaches the far boundary, the assumed geometry and drug inventory must be reconsidered.

A useful experiment plots corrected released mass per area against $\sqrt{t}$ and checks whether the apparent slope changes with medium flow or formulation thickness. A straight segment alone does not identify the mechanism. External transport resistance, swelling or changing diffusivity can invalidate the model even if a short data segment looks nearly linear. Sampling correction in drug release testing and a specified exposed area are therefore part of interpreting a fitted $k_H$.

A perfect sink condition in drug release is an idealized receiving boundary that removes released drug fast enough for its concentration there to be treated as zero. In diffusion-controlled drug release, this preserves the largest concentration drop available at the exposed boundary. It is a condition on transport at the release surface, rather than a statement that the entire apparatus contains no drug.

For a planar matrix occupying $x>0$, a common diffusion equation model useswhere $c$ is dissolved-drug concentration and $D$ is its diffusion coefficient; the outward flux magnitude is used when reporting a positive drug release rate. A finite mass-transfer boundary in drug release instead allows a nonzero surface concentration. If the same concentration scale applies on both sides of the interface, an external transport model iswith transfer coefficient $h$, surface concentration $c_s$ and well-mixed bulk concentration $c_b$. A small $c_b$ does not force $c_s$ to be small when a stagnant layer or membrane imposes substantial resistance.

An original finite-reservoir example separates capacity from transport. Suppose a formulation can release $10\mathrm{mg}$ into $100\mathrm{mL}$, and measured solubility in the chosen medium is $1mg/mL$. Even after complete release the well-mixed bulk concentration is only $0.10mg/mL$. In a simple saturated-interface dissolution model $J=h(c_{\mathrm{sat}}-c_b)$, that concentration still reduces flux to $90\%$ of its zero-bulk-concentration value. Large capacity makes a zero-concentration approximation plausible to a chosen tolerance; it does not make the approximation exact.

A useful experimental test compares in vitro drug release test curves while increasing receiving volume or flow, with temperature and medium chemistry controlled. Sampling and medium replacement require sampling correction in drug release testing. If increasing external transport changes the curve, apparatus resistance or accumulation may still matter. The FDA’s primary account of adaptive perfusion describes pressure-driven filtration designed to avoid rate limitation by a passive dialysis membrane.^[ref]

The ideal boundary should be distinguished from a method’s practical sink criterion. The FDA’s 1997 dissolution guidance discusses medium, apparatus and agitation together and explicitly allows justified non-sink tests; a zero boundary is a modelling choice to be checked against the actual experiment.^[ref]

Sampling correction in drug release testing is a material-balance adjustment for the substance removed, added or diluted when a receiver is sampled repeatedly. A measured concentration describes material still present at that moment; cumulative release also includes material withdrawn earlier. The distinction belongs to interpretation of an in vitro drug release test, whose transport and separation conditions are part of the measured system.^[ref]

Let $V_n$ and $C_n$ be receiver volume and concentration just before the $n$th withdrawal. At earlier observations $j<n$, remove volume $v_j$ at concentration $C_j$ and add volume $w_j$ containing concentration $b_j$. With initial receiver amount $M_{\mathrm{init}}$, conservation gives the cumulative amount contributed by the formulation:The terms account for material remaining, material already removed and material supplied from elsewhere. The equation assumes that measured species is conserved and that the receiver is well mixed; adsorption or chemical transformation requires additional terms.

For initially blank medium, blank replacement and constant volume $V$, this reduces to $V{C}_n+{\sum }_{j<n}{v}_j{C}_j$. If the aliquots are not replaced, the current volume instead satisfies $V_n=V_0-{\sum }_{j<n}{v}_j$.

Consider an illustrative receiver initially containing $100\mathrm{mL}$. Withdraw $10\mathrm{mL}$ at $C_1=0.20\mathrm{mg}\mathrm{m}{\mathrm{L}}^{-1}$ without replacement. At the next observation, $V_2=90\mathrm{mL}$ and $C_2=0.30\mathrm{mg}\mathrm{m}{\mathrm{L}}^{-1}$, so the cumulative amount is $27+2=29\mathrm{mg}$. Incorrectly retaining the initial volume in the calculation would give $32\mathrm{mg}$. These chosen numbers illustrate accounting, not a formulation specification.

The sampling schedule and replacement protocol must therefore accompany a release curve. A decline in concentration after dilution does not imply that previously released material returned to the carrier. Similarly, a finite-difference drug release rate should be calculated from corrected cumulative amounts, with uncertainty and any shared measurement errors carried through the calculation.

Takeru Higuchi, credited as T. Higuchi in his 1963 paper, developed mathematical descriptions of diffusion-controlled drug release from solid matrices. The University of Kansas archive holds that exact paper among his personal papers, establishing the connection between the initial-only byline and the full name.^[ref]

The paper distinguished a uniform matrix serving as the diffusional medium from a granular matrix penetrated by a solvent. It considered planar and spherical geometries, rather than treating all sustained release as a single first-order process.^[ref] The resulting models connect formulation geometry and material properties with a measurable drug release rate.

A simplified planar derivation illustrates the Higuchi equation. Assume a stationary matrix with constant diffusion coefficient $D$, excess undissolved drug, a perfect sink condition in drug release at its exposed face, and a slowly moving depletion boundary at depth $h(t)$. Approximate the dissolved-drug concentration as linear from zero at the exposed face to its solubility $C_s$ at that boundary. If initial total loading per unit volume is $C_0$, the amount released per exposed area isbecause the depleted layer retains a triangular dissolved-drug profile. The outward mass flux is approximately $D{C}_s/h$, so mass conservation givesThus the cumulative released amount is proportional to $\sqrt{t}$ in this model, whereas its derivative decreases as $t^{-1/2}$. The high-loading approximation $C_0\gg C_s$ makes the slowly moving boundary assumption more plausible; the result is not a general solution for an arbitrary dissolving or swelling material.

For an original illustration, let $Q=k_H\sqrt{t}$ with $k_H=2\mathrm{mg}\mathrm{c}{\mathrm{m}}^{-2}{\mathrm{h}}^{-1/2}$. The cumulative release is $2\mathrm{mg}\mathrm{c}{\mathrm{m}}^{-2}$ at one hour and $4\mathrm{mg}\mathrm{c}{\mathrm{m}}^{-2}$ at four hours, but the instantaneous rates per area are respectively $1$ and $0.5\mathrm{mg}\mathrm{c}{\mathrm{m}}^{-2}{\mathrm{h}}^{-1}$. These are chosen model values. They show why sustained release need not be constant-rate release. Finite thickness, depletion of the solid phase, changing solubility or external transport resistance can end this regime. Measuring release tests the model's transport assumptions; a square-root fit alone does not uniquely identify them.